Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of FYX-051 in Hyperuricemia (with or without Gout)
jRCT2080221050Phase 3
- Sponsor
- Fuji Yakuhin
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of topiroxostat in hyperuricemia, gout, nephrolithiasis and 3 more, sponsored by Fuji Yakuhin. Primary endpoints: Long-term safety of FYX-051 and Long-term efficacy of FYX-051 on serum urate.
02
Drugs
topiroxostat
03
Conditions
hyperuricemiagoutnephrolithiasishypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on jRCT2080221050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221050.